The burden-of-illness study on osteoporosis in the Slovenian female population

被引:17
作者
Dzajkovska, Bijana
Wertheimer, Albert I.
Mrhar, Ales
机构
[1] Millennium Pharmaceut Ltd, London W4 5YA, England
[2] Fac Pharm, Dept Biopharmaceut & Pharmacokinet, Ljubljana 1000, Slovenia
[3] Temple Univ, Sch Pharm, Ctr Pharmaceut Hlth Serv Res, Philadelphia, PA 19140 USA
来源
PHARMACY WORLD & SCIENCE | 2007年 / 29卷 / 04期
关键词
bone fractures; burden-of-illness; costs; economics; health policy; osteoporosis; Slovenia;
D O I
10.1007/s11096-007-9091-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study objective This burden-of-illness study on osteoporosis was performed with the main goal to estimate the economic implications of osteoporosis for the Slovenian healthcare system. Methods A variety of sources was used to quantify the utilization of resources in 2003, and the appropriate unit costs were assigned to the identified resources. Main outcome measures The study included all direct and indirect costs that arise from treatment of osteoporosis and consequent hip, spine and wrist fractures in total Slovene postmenopausal population in 2003. Results We estimated the total burden of postmenopausal osteoporosis in Slovenia for 2003 to be over SIT 7.55 billion (approximately epsilon 31.5 million); among that, 45% or SIT 3.39 billion (epsilon 14.2 million) belong to drug expenditures for osteoporosis treatment and prevention; 29% or SIT 2.2 billion (epsilon 9.2 million) include indirect costs for osteoporosis morbidity and mortality, and 26% or SIT 1.95 billion (epsilon 8.1 million) belong to direct costs for treatment, hospitalization, and rehabilitation of osteoporotic fractures. Total costs on osteoporotic fractures were however subject to an approximation due to the expert panel-based estimate of proportion of osteoporosis-caused fractures and the limited data on resource utilization for fracture treatment. Conclusion Osteoporosis is a costly disease with a significant burden to society and needs to be viewed as an important problem with a complex long-term impact.
引用
收藏
页码:404 / 411
页数:8
相关论文
共 18 条
[1]   Prevention of osteoporosis: Cost-effectiveness of different pharmaceutical treatments [J].
AnkjaerJensen, A ;
Johnell, O .
OSTEOPOROSIS INTERNATIONAL, 1996, 6 (04) :265-275
[2]   Incremental cost of medical care after hip fracture and first vertebral fracture: The Rotterdam Study [J].
De Laet, CEDH ;
van Hout, BA ;
Burger, H ;
Weel, AEAM ;
Hofman, A ;
Pols, HAP .
OSTEOPOROSIS INTERNATIONAL, 1999, 10 (01) :66-72
[3]   The cost of treating osteoporotic fractures in the United Kingdom female population [J].
Dolan, P ;
Togerson, DJ .
OSTEOPOROSIS INTERNATIONAL, 1998, 8 (06) :611-617
[4]  
FERK J, 2002, ZDRAVNISKI VESTNIK, V71, P41
[5]  
*I VAR ZDR REP SLO, 2003, ZDRAVSTV STAT LET
[6]  
*IVZ, 2003, AMB PREDP ZDRAV SLOV
[7]   The burden of osteoporotic fractures: A method for setting intervention thresholds [J].
Kanis, JA ;
Oden, A ;
Johnell, O ;
Jonsson, B ;
de Laet, C ;
Dawson, A .
OSTEOPOROSIS INTERNATIONAL, 2001, 12 (05) :417-427
[8]   A practical guide for calculating indirect costs of disease [J].
Koopmanschap, MA ;
Rutten, FFH .
PHARMACOECONOMICS, 1996, 10 (05) :460-466
[9]   Direct costs of osteoporosis for New Zealand women [J].
Lane, A .
PHARMACOECONOMICS, 1996, 9 (03) :231-245
[10]   The burden of osteoporosis in California, 1998 [J].
Max, W ;
Sinnot, P ;
Kao, C ;
Sung, HY ;
Rice, DP .
OSTEOPOROSIS INTERNATIONAL, 2002, 13 (06) :493-500